Okayasu Kaori, Takeda Yuichiro, Kojima Jun, Yoshizawa Atsuto, Kobayashi Nobuyuki, Sugiyama Haruhito, Kudo Koichiro
Department of Respiratory Medicine, International Medical Center of Japan, Tokyo, Japan.
Intern Med. 2006;45(22):1303-7. doi: 10.2169/internalmedicine.45.1800. Epub 2006 Dec 15.
A 44-year-old man was treated with amiodarone for dilated cardiomyopathy. After 53 months, he developed amiodarone-induced interstitial pneumonia. Amiodarone treatment was terminated, and the patient was given corticosteroids. These treatments were effective. However, pneumonitis recurred whenever prednisolone was reduced to less than 5 mg per day. Considering the patient's background characteristics, we considered his body mass index (BMI, kg/m(2)) and found his to be high. When four additional patients with amiodarone pulmonary toxicity were reviewed at our institute, a correlation between BMI and the duration of shadow disappearance was found (R(2)=0.8695). Because amiodarone is lipophilic, the patient's high BMI might have influenced the repeated appearance of pulmonary toxicity.
一名44岁男性因扩张型心肌病接受胺碘酮治疗。53个月后,他患上了胺碘酮诱发的间质性肺炎。胺碘酮治疗终止,患者接受了皮质类固醇治疗。这些治疗有效。然而,每当泼尼松龙减至每日低于5毫克时,肺炎就会复发。考虑到患者的背景特征,我们计算了他的体重指数(BMI,kg/m²),发现其较高。当我们研究所对另外4例胺碘酮肺毒性患者进行复查时,发现BMI与阴影消失持续时间之间存在相关性(R² = 0.8695)。由于胺碘酮具有亲脂性,患者较高的BMI可能影响了肺毒性的反复出现。